Preliminary program thematic sessions
 

Opening lecture: Anthony Hickey, RTI

Session 1:  Formulations and devices
Chair: Paolo Colombo, University of Parma

  • Formulation of high-dose antimicrobial drugs for dry powder inhalation 
    Pavan Muttil, University of New Mexico
  • Multi-antimicrobial-drug compatible dry powder inhalers  
    Anne de Boer, University of Groningen

Session 2:  Submitted abstracts session
Chair: Erik Frijlink, University of Groningen

  • Selection of submitted abstracts will be presented on-stage

Session 3: Development and implementation

  • The quest for potentiators for antimicrobial drugs 
    Jurriaan de Steenwinkel, Erasmus Medical Centre Rotterdam
  • Implementation of a new drug (regime) into a TB treatment guideline    
    Dennis Falzon, WHO

Session 4: Preclinical, models, and modelling
Chair: Rany Condos, New York University

  • The power of in vitro models in the continuous battle against M. tuberculosis
    Tawanda Gumbo, Baylor Research Institute
  • The value of animal models in the development of inhaled TB therapies                                                                                                                    Lucila Garcia-Contreras, University of Oklahoma
  • The role of Functional Respiratory Imaging (FRI) in TB treatment
    Wim Vos, consultant

Session 5: Clinical trials and use
Chairs: Edward Nardell, Harvard Medical School & Tjip van der Werf, Beatrixoord (UMCG)

  • The added value of pharmacokinetics and pharmacodynamics for old and repurposed TB drugs                                                                        Simon Tiberi, Barts Health NHS Trust
  • How to choose and evaluate a new treatment regimen for MDR-TB                                                                                                                                Martin Grobusch, Amsterdam Medical Center / University of Amsterdam
  • The pros and cons of inhalation of new and current TB drugs
    Onno Akkerman, University Medical Center Groningen